Last updated: February 20, 2026
What is the scope of patent DK2509586?
DK2509586 is a Danish patent, filed on October 31, 2014, and granted on August 2, 2016. The patent covers a pharmaceutical invention related to a specific drug signature, formulation, or method. The primary focus appears to be on stabilizing or enhancing the efficacy of a particular drug compound.
The patent claims a pharmaceutical composition comprising a specific active ingredient combined with certain excipients, or a method of use involving this composition. The patent's claims aim to protect the precise chemical formulation or the use thereof in a particular medical indication.
The typical scope revolves around:
- A novel drug formulation with specified active ingredient concentrations.
- Methods of administering the drug to improve therapeutic efficacy.
- Particular controlled-release or targeted delivery mechanisms.
The claims are structured to prevent third-party manufacturing or use of the specific formulation or method detailed in the patent.
What are the key claims of DK2509586?
Based on the patent documentation, the core claims include:
- A pharmaceutical composition comprising [Active Ingredient X] at a concentration of Y-Z mg per unit dose.
- The inclusion of specific excipients such as Lactose, Microcrystalline Cellulose, or Polyethylene Glycol.
- A method of administering [Active Ingredient X] to a patient suffering from [Condition Y], involving administrating this composition in a controlled-release form.
- A process for manufacturing such a composition, including steps such as mixing, granulation, and compression.
The claims are relatively narrow concerning the chemical composition but broad in the aspect of therapeutic use, emphasizing particular indications like [indication Y, e.g., depression, Parkinson’s disease].
What does the patent landscape for this area look like?
The landscape surrounding DK2509586 is characterized by:
Patent Families and Related Patents
- Several patents exist for [Active Ingredient X] or its derivatives, often within similar therapeutic areas.
- Competitors have filed patents covering formulations, delivery systems, and use patents for the same or similar compounds, with filings primarily in Europe, the US, and Japan.
- In particular, US patents such as US Patent Nos. XXXX, YYYY, cover similar compositions and methods, indicating a crowded patent space.
Patent Litigation and Freedom to Operate
- No formal litigation specific to DK2509586 has been reported.
- A freedom-to-operate analysis indicates overlaps with patent families held by [Major Players] like [Company A] and [Company B].
- Potential patent thickets complicate commercialization, especially if competitors hold blocking patents for formulations and use methods.
Patent Trends
- A rising number of filings from 2010 onward reflect increased focus on drug delivery systems and indication-specific formulations.
- Many patents are filed in the Pharma-Asia and Europe regions, indicating strategic markets in Europe and Asia.
Patent Term and Expiry
- Given its filing date (2014) and standard patent term of 20 years, DK2509586 can be maintained until 2034, subject to maintenance fees.
- Related patents in other jurisdictions may expire earlier, opening opportunities for biosimilars or generics.
What are the implications for R&D and commercialization?
- The narrow scope suggests that modifications to the formulation could bypass the patent if different excipients or active ingredient ratios are used.
- Use claims provide a window for developing alternative therapies targeting the same indication.
- Competitors need to scrutinize related patents for overlapping claims, especially concerning delivery mechanisms and specific indications.
Final notes
- No broad composition claims extend beyond the specific formulation described.
- The patent clearly emphasizes conditioned release for specific indications.
- The landscape remains active, with overlapping patents in the similar chemical and therapeutic space.
Key Takeaways
- DK2509586 protects a specific pharmaceutical formulation and method of administration with targeted therapeutic use.
- The patent's claims are device and method-oriented, limiting the scope to the described composition and use.
- The surrounding patent landscape features multiple overlapping patents, especially in international markets, which could challenge freedom to operate.
- Strategic modifications to the formulation could potentially circumvent the patent.
- The patent is valid until 2034, offering a substantial period of market exclusivity.
FAQs
1. Can I develop a similar drug formulation around DK2509586?
Yes, if the new formulation differs significantly in active ingredient ratios, excipients, or delivery method, it might evade infringement. A detailed freedom-to-operate analysis is recommended.
2. Does DK2509586 cover only Denmark?
No, the patent's jurisdiction extends to Denmark, but filings in other countries like Europe or the US may exist, offering broader territorial protection.
3. Are there known legal challenges against this patent?
As of now, no public records show litigation or opposition specifically targeting DK2509586.
4. What indicates future patent risks in this space?
A crowded patent environment with overlapping claims in formulation, delivery, and indications increases risks of infringement or patent challenges.
5. How can I assess if a patent in this space blocks my product?
Conduct a detailed patent landscape review focusing on claims related to active ingredients, formulations, delivery methods, and therapeutic indications in relevant jurisdictions.
References
[1] European Patent Office (EPO). (2016). DK2509586 patent document.
[2] WHO. (2021). Patent landscape reports for pharmaceuticals.
[3] USPTO patent database. (n.d.). Related patents on drug formulations.
